These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

644 related articles for article (PubMed ID: 18799218)

  • 1. Suppression of experimental myasthenia gravis by a B-cell epitope-free recombinant acetylcholine receptor.
    Yi HJ; Chae CS; So JS; Tzartos SJ; Souroujon MC; Fuchs S; Im SH
    Mol Immunol; 2008 Nov; 46(1):192-201. PubMed ID: 18799218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment.
    Im SH; Barchan D; Fuchs S; Souroujon MC
    J Clin Invest; 1999 Dec; 104(12):1723-30. PubMed ID: 10606626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of tolerogen conformation in induction of oral tolerance in experimental autoimmune myasthenia gravis.
    Im SH; Barchan D; Souroujon MC; Fuchs S
    J Immunol; 2000 Oct; 165(7):3599-605. PubMed ID: 11034361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective potential of experimental autoimmune myasthenia gravis in Lewis rats by IL-10-modified dendritic cells.
    Duan RS; Adikari SB; Huang YM; Link H; Xiao BG
    Neurobiol Dis; 2004 Jul; 16(2):461-7. PubMed ID: 15193302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral administration of a dual analog of two myasthenogenic T cell epitopes down-regulates experimental autoimmune myasthenia gravis in mice.
    Paas-Rozner M; Dayan M; Paas Y; Changeux JP; Wirguin I; Sela M; Mozes E
    Proc Natl Acad Sci U S A; 2000 Feb; 97(5):2168-73. PubMed ID: 10681457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of CD40 ligand suppresses chronic experimental myasthenia gravis by down-regulation of Th1 differentiation and up-regulation of CTLA-4.
    Im SH; Barchan D; Maiti PK; Fuchs S; Souroujon MC
    J Immunol; 2001 Jun; 166(11):6893-8. PubMed ID: 11359850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role for interferon-gamma in rat strains with different susceptibility to experimental autoimmune myasthenia gravis.
    Wang HB; Shi FD; Li H; van der Meide PH; Ljunggren HG; Link H
    Clin Immunol; 2000 May; 95(2):156-62. PubMed ID: 10779409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.
    Atassi MZ; Oshima M; Deitiker P
    Crit Rev Immunol; 2001; 21(1-3):1-27. PubMed ID: 11642597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of the adenosine A2A receptor attenuates experimental autoimmune myasthenia gravis severity.
    Li N; Mu L; Wang J; Zhang J; Xie X; Kong Q; Tang W; Yao X; Liu Y; Wang L; Wang G; Wang D; Jin L; Sun B; Li H
    Eur J Immunol; 2012 May; 42(5):1140-51. PubMed ID: 22539289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral administration of acetylcholine receptor: effects on experimental myasthenia gravis.
    Okumura S; McIntosh K; Drachman DB
    Ann Neurol; 1994 Nov; 36(5):704-13. PubMed ID: 7979216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Naturally occurring CD4+CD25+ regulatory T cells prevent but do not improve experimental myasthenia gravis.
    Nessi V; Nava S; Ruocco C; Toscani C; Mantegazza R; Antozzi C; Baggi F
    J Immunol; 2010 Nov; 185(9):5656-67. PubMed ID: 20881192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The limitation of IL-10-exposed dendritic cells in the treatment of experimental autoimmune myasthenia gravis and myasthenia gravis.
    Xiao BG; Duan RS; Zhu WH; Lu CZ
    Cell Immunol; 2006 Jun; 241(2):95-101. PubMed ID: 17005165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cell reactivity to acetylcholine receptor in rats orally tolerized against experimental autoimmune myasthenia gravis.
    Wang ZY; Qiao J; Melms A; Link H
    Cell Immunol; 1993 Dec; 152(2):394-404. PubMed ID: 8258147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of experimental myasthenia gravis, a B cell-mediated autoimmune disease, by blockade of IL-18.
    Im SH; Barchan D; Maiti PK; Raveh L; Souroujon MC; Fuchs S
    FASEB J; 2001 Oct; 15(12):2140-8. PubMed ID: 11641240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Animal models of myasthenia gravis.
    Christadoss P; Poussin M; Deng C
    Clin Immunol; 2000 Feb; 94(2):75-87. PubMed ID: 10637092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B-T lymphocyte interactions in experimental autoimmune myasthenia gravis: autoantibody mediated up-regulation of the response of acetylcholine receptor-specific T lymphocytes.
    Zhang Y; Tzartos S
    Immunology; 1992 Dec; 77(4):571-6. PubMed ID: 1283599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention and reversal of experimental autoimmune myasthenia gravis by a monoclonal antibody against acetylcholine receptor-specific T cells.
    Xu L; Villain M; Galin FS; Araga S; Blalock JE
    Cell Immunol; 2001 Mar; 208(2):107-14. PubMed ID: 11333143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoimmune responses against acetylcholine receptor: T and B cell collaboration and manipulation by synthetic peptides.
    Atassi MZ; Oshima M
    Crit Rev Immunol; 1997; 17(5-6):481-95. PubMed ID: 9419435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specificity of the T cell immune response to acetylcholine receptor in experimental autoimmune myasthenia gravis. Response to subunits and synthetic peptides.
    Fujii Y; Lindstrom J
    J Immunol; 1988 Mar; 140(6):1830-7. PubMed ID: 2450133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous immunoglobulin suppresses experimental myasthenia gravis: immunological mechanisms.
    Zhu KY; Feferman T; Maiti PK; Souroujon MC; Fuchs S
    J Neuroimmunol; 2006 Jul; 176(1-2):187-97. PubMed ID: 16730380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.